When was Tactiva Therapeutics founded?

Tactiva Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Tactiva Therapeutics located?

Tactiva Therapeutics is headquartered in Buffalo, United States.

Who is the current CEO of Tactiva Therapeutics?

Matthew Colpoys of Tactiva Therapeutics.

How many employees does Tactiva Therapeutics have?

As of Aug 31, 2026, the latest employee count at Tactiva Therapeutics is 5.

Is Tactiva Therapeutics a funded company?

Tactiva Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 03, 2018.

When was the latest funding round of Tactiva Therapeutics?

Tactiva Therapeutics' latest funding was a $***** Series A round on Dec 03, 2018, with participation from 3 investors. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.97B in funding in 2026 to date.

Where does Tactiva Therapeutics rank among its competitors?

Tactiva Therapeutics ranks 1248th amongst 3422 active competitors, of which 1151 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Tactiva Therapeutics?

Tactiva Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Tactiva Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Tactiva Therapeutics is a series A company based in Buffalo (United States), founded in 2017 by Matthew Colpoys. It operates as an Innovative cancer immunotherapy company developing next-generation adoptive T cell therapies. Tactiva Therapeutics has raised $35M in funding from Panacea Venture. The company has 3422 active competitors, including 1151 funded and 806 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Innovative cancer immunotherapy company developing next-generation adoptive T cell therapies. They are focused on engineering immune cells for potent cancer treatment, specifically targeting cancer in a specific, efficient, and durable manner. Their approach utilizes a unique class of CD4 T cells to enhance the anti-tumor function of CD8 T cells, directly targeting tumor cells. The platform harnesses the synergistic effects of CD8-TCRs and CD4-TCRs, and HSC derived T cells, to provide durable remission for cancer patients. This immuno-oncology company specializes in potent cancer immunotherapy using a dual T cell receptor approach, including genetic modification of patients’ mature T cells and reprograming patient derived hematopoietic stem cells (HSCs). This creates a continual, long-term source of cancer-fighting T cells, leading to sustained attack on cancer cells.

Website: tactivatherapeutics.com
Email ID: *****@tactivatherapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Buffalo, United States

Stage

Series A

Total Funding

$35M in 1 round

Latest Funding Round

Series A, Dec 03, 2018, $*****

Investors

Panacea Venture & 2 more

Ranked

1248^th among 3422 active competitors

Employee Count

5 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3174 more

View Tactiva Therapeutics' full profile

Tactiva Therapeutics has raised a total funding of $35M over 1 round. Its latest funding round was a Series A round on Dec 03, 2018 for $*****. 3 investors participated in its latest round. Tactiva Therapeutics has 3 institutional investors.

Here is the list of recent funding rounds of Tactiva Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 03, 2018	4257543	Series A	9105695	9542831	3821757	8366474

Access funding benchmarks and valuations. Sign up today!

View details of Tactiva Therapeutics's funding rounds and investors

The founders of Tactiva Therapeutics is Matthew Colpoys.

Here are the details of Tactiva Therapeutics' key team members:

Matthew Colpoys: CEO & Co-Founder of Tactiva Therapeutics.
Contact Info: 1 email address

View details of Tactiva Therapeutics's Founder profiles and Board Members

Tactiva Therapeutics' employee count trend

Tactiva Therapeutics has 5 employees as of Aug 26. Here is Tactiva Therapeutics's employee count trend over the years:

Employee count trend for Tactiva Therapeutics

Uncover Tactiva Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tactiva Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Tactiva Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1248th	Tactiva Therapeutics 2017, Buffalo (United States), Series A	Innovative cancer immunotherapy company developing next-generation adoptive T cell therapies	$35M	VI Ventures, Panacea Venture & 1 others	38/100